INCY logo

Incyte Corporation

INCY
Healthcare|Biotechnology|US
$119.65
+1.64 (+1.39%)
DCF Value
$113.08
Tangible Book / Share
$26.60
Graham Number
$35.21
Cash / Share
$18.97

About

Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.

Stock Price

+13.7%(1Y)
1M
+6.1%
3M
-0.8%
6M
+21.4%
YTD
+21.1%
1Y
+12.9%
3Y
+121.3%
5Y
+80.0%

Pipeline Summary

497 total trials
191
Phase 1
267
Phase 2
78
Phase 3
3
Phase 4
Recruiting: 96Terminated: 94Completed: 210Active: 50Not Yet Recruiting: 12Withdrawn: 22Approved: 3Unknown: 2Available: 2No Longer Available: 6

Active Trials (146)

Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma
NCT07731789Classic Follicular Lymphoma
Phase 2Recruiting
Enrollment: 30 participants
A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
NCT03414229Sarcoma
Phase 2Active
Enrollment: 30 participants
Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)
NCT07424222Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
Phase 1Recruiting
Enrollment: 16 participants
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
NCT03110822Multiple Myeloma
Phase 1Recruiting
Enrollment: 134 participants
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
NCT04225039Glioblastoma
Phase 2Active
Enrollment: 39 participants

BioScore

5.3/10
Watchlist

Key Facts

Market Cap$24.39B
Employees2,844 (+9% YoY)
CEOWilliam J. Meury
IPO DateNov 4, 1993
Beta0.78
52-Week Range$89.25 – $132.6
Avg Volume1,696,249
ExchangeNASDAQ
Websiteincyte.com

Ownership

Float99.1%
Shares Outstanding203.8M

Recent Insider Trades

Tray ThomasSELL
Nov 3, 2026610 shares @ $118.96
CAGNONI PABLO JOPTION EX.
Oct 15, 2026925 shares @ $64.25
CAGNONI PABLO JOPTION EX.
Oct 15, 2026455 shares @ $61.18
CAGNONI PABLO JOPTION EX.
Oct 15, 2026423 shares @ $61.76
CAGNONI PABLO JOPTION EX.
Oct 15, 2026839 shares @ $71.93

Peers

AVBPArriVent BioPharma, Inc.
$672.6M
CGEMCullinan Therapeutics, Inc.
$695.1M
EXELExelixis, Inc.
$17.49B
GMABGenmab A/S
$32.98B
LEGNLegend Biotech Corporation
$4.33B
LGNDLigand Pharmaceuticals Incorporated
$6.12B
NRIXNurix Therapeutics, Inc.
$1.67B
REGNRegeneron Pharmaceuticals, Inc.
$93.54B
Data last updated: Nov 9, 2026, 04:15 AM